The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day to
sunitinib at 50 mg/day in the treatment of patients with gastro-intestinal stromal tumor
(GIST) after progression with imatinib.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT01694277.
Masitinib is a selective tyrosine kinase inhibitor with potent activity against wild-type
c-Kit, the juxta membrane domain of c-Kit, and PDGFR. Masitinib is also thought to
promote survival via modulation of immunostimulation-mediated anticancer effects and
modulation of the tumor microenvironment. The objective is to compare the efficacy and
safety of masitinib at 12 mg/kg/day with respect to sunitinib at 50 mg/day in the
treatment of imatinib-resistant gastro-intestinal stromal tumor (GIST).
Lead OrganizationAB Science
